Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Intestinal Lipase Inhibitor [EPC]
Orlistat is a potent intestinal lipase inhibitor indicated for weight management and obesity treatment. It works by preventing the absorption of dietary fats in the gastrointestinal tract, making it a unique non-systemic option for chronic weight loss.
Name
Orlistat
Raw Name
ORLISTAT
Category
Intestinal Lipase Inhibitor [EPC]
Drug Count
4
Variant Count
5
Last Verified
February 17, 2026
RxCUI
314153, 692876, 723846, 226917
UNII
95M8R751W8
About Orlistat
Orlistat is a potent intestinal lipase inhibitor indicated for weight management and obesity treatment. It works by preventing the absorption of dietary fats in the gastrointestinal tract, making it a unique non-systemic option for chronic weight loss.
Detailed information about Orlistat
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Orlistat.
Orlistat is a specialized pharmacological agent classified as an Intestinal Lipase Inhibitor [EPC]. Unlike many other weight management medications that act on the central nervous system to suppress appetite or increase metabolism, Orlistat exerts its therapeutic effects locally within the lumen (interior space) of the stomach and small intestine. It was first approved by the U.S. Food and Drug Administration (FDA) in 1999 under the brand name Xenical for prescription use, and later in 2007 as a lower-dose over-the-counter (OTC) version known as Alli.
Orlistat belongs to a class of drugs called lipase inhibitors. Its primary role is to assist in weight loss and weight maintenance when used in conjunction with a reduced-calorie, low-fat diet. Because it is minimally absorbed into the bloodstream, it is often favored by healthcare providers for patients who may be sensitive to the systemic side effects of stimulant-based weight loss medications. According to the FDA-approved labeling, Orlistat is indicated for the treatment of obesity in patients with an initial body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of other risk factors such as hypertension (high blood pressure), diabetes mellitus, or dyslipidemia (abnormal cholesterol levels).
The mechanism of action for Orlistat is both elegant and highly specific. It targets the enzymes responsible for breaking down dietary fats (triglycerides). These enzymes, known as gastric and pancreatic lipases, are secreted by the stomach and pancreas into the digestive tract. Under normal conditions, these lipases break down large triglyceride molecules into smaller, absorbable components: free fatty acids and monoglycerides.
When Orlistat is present in the gut, it forms a covalent bond (a strong chemical link) with the active serine site of these lipase enzymes. This inactivation prevents the enzymes from hydrolyzing (breaking down) the fat from the food you eat. Because the fat remains in its large, triglyceride form, it cannot be absorbed through the intestinal wall. Instead, the unabsorbed fat—representing approximately 25% to 30% of the fat consumed in a meal—is excreted through the feces. By reducing the caloric intake from fat, Orlistat helps create a caloric deficit, which is the fundamental requirement for weight loss. It is important to note that Orlistat does not affect the absorption of carbohydrates or proteins; it is strictly a fat-blocker.
Understanding the pharmacokinetics of Orlistat is essential for clinical management, as it differs significantly from most oral medications.
Orlistat is FDA-approved for several specific indications related to weight management:
Off-label, some healthcare providers may use Orlistat to manage certain types of hyperlipidemia or to improve insulin sensitivity in patients with metabolic syndrome, though these are not primary indications.
Orlistat is available in two primary strengths and forms:
Both forms are intended to be used alongside a nutritionally balanced, reduced-calorie diet where approximately 30% of calories come from fat.
> Important: Only your healthcare provider can determine if Orlistat is right for your specific condition. A thorough evaluation of your cardiovascular health and nutritional status is required before starting treatment.
The standard adult dosage for Orlistat depends on whether you are using the prescription or over-the-counter version:
Clinical data suggests that doses above 120 mg three times daily do not result in additional weight loss. If a meal is occasionally missed or contains no fat, the dose of Orlistat can be omitted for that specific meal, as the drug will have no fat to act upon.
For adolescents aged 12 to 16 years, the dosage is the same as the adult prescription dose: 120 mg three times daily with meals containing fat. Safety and efficacy for children under the age of 12 have not been established. Pediatric use must always be supervised by a pediatrician or specialist in adolescent weight management to ensure that growth and development are not negatively impacted by potential vitamin deficiencies.
Because Orlistat is minimally absorbed systemically, dosage adjustments are generally not required for patients with renal (kidney) impairment. However, patients with a history of calcium oxalate kidney stones should be monitored closely, as Orlistat can increase the levels of oxalate in the urine.
No dosage adjustment is necessary for patients with hepatic (liver) impairment, as the drug does not undergo significant hepatic metabolism.
Clinical trials did not include sufficient numbers of patients over 65 to determine if they respond differently than younger patients. However, given its non-systemic nature, no specific age-based dosage adjustment is currently recommended, though caution is advised due to the higher prevalence of other comorbidities in the elderly.
To maximize the efficacy of Orlistat and minimize side effects, follow these specific instructions:
If you miss a dose and it is within one hour of your last meal, take the dose as soon as you remember. If more than one hour has passed since your meal, skip the missed dose and continue with your next scheduled meal and dose. Do not take two doses at once to make up for a missed one.
In the event of an overdose, contact a poison control center or seek emergency medical attention immediately. While systemic toxicity is unlikely due to low absorption, a significant overdose may lead to severe gastrointestinal symptoms, such as intense abdominal cramping or uncontrollable oily discharge. Medical professionals will typically monitor the patient for any signs of malabsorption or GI distress.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Successful weight loss with Orlistat requires a long-term commitment to dietary changes and physical activity.
The side effects of Orlistat are primarily gastrointestinal (GI) in nature and are directly related to the drug's mechanism of blocking fat absorption. These are often referred to as "treatment effects" because they indicate the drug is working. They include:
These symptoms typically appear within the first few weeks of treatment and may subside as the patient learns to better manage their dietary fat intake. If a patient consumes a high-fat meal, these side effects will be much more severe.
> Warning: Stop taking Orlistat and call your doctor immediately if you experience any of these symptoms. These may indicate a severe reaction or organ damage.
With prolonged use, the most significant concern is Chronic Vitamin Malabsorption. If a patient does not take a multivitamin supplement as directed, they may develop deficiencies in vitamins A, D, E, and K.
Additionally, some studies have investigated the potential for Orlistat to change the composition of the gut microbiome, though the long-term clinical significance of these changes is still being researched.
As of 2026, there are no FDA Black Box Warnings for Orlistat. However, the FDA did add a warning to the label in 2010 regarding rare but serious liver injury. Patients are advised to be aware of the signs of liver problems and to report them to their healthcare provider immediately.
Report any unusual symptoms to your healthcare provider. Keeping a food diary can help you identify which high-fat foods are triggering gastrointestinal side effects, allowing you to adjust your diet for better tolerability.
Orlistat is not a "miracle pill" and must be used as part of a comprehensive weight management program. It is not intended for people who are not overweight. Because it changes how your body digests fat, it can significantly alter the absorption of other medications and nutrients. Patients must be committed to a low-fat diet to avoid distressing gastrointestinal side effects.
No FDA black box warnings for Orlistat.
While rare, cases of subacute liver failure and fulminant hepatic failure have been reported. If you develop unexplained fatigue, jaundice (yellowing of the skin), or dark urine, discontinue the drug immediately and seek medical evaluation. Your doctor may perform liver function tests (LFTs) if liver injury is suspected.
Orlistat can increase the amount of oxalate in your urine (hyperoxaluria). This can lead to the formation of calcium oxalate stones or, in severe cases, oxalate nephropathy and kidney failure. Patients with pre-existing kidney disease or those at risk for stones should use Orlistat with extreme caution.
Weight loss, in general, is associated with an increased risk of gallstones. Patients taking Orlistat who experience severe pain in the upper right abdomen should be evaluated for gallbladder issues.
Though rare, systemic hypersensitivity reactions have occurred. Patients with a known allergy to Orlistat or any of the inactive ingredients (such as microcrystalline cellulose or sodium starch glycolate) must avoid this medication.
Healthcare providers typically monitor the following during Orlistat therapy:
Orlistat is not known to cause drowsiness or impair cognitive function. It is generally considered safe to drive or operate machinery while taking this medication. However, the sudden onset of fecal urgency may be a distraction; patients should ensure they understand how the drug affects their bowel habits before engaging in long-distance driving.
There is no direct chemical interaction between Orlistat and alcohol. However, many alcoholic beverages are high in calories and provide no nutritional value, which can hinder weight loss goals. Furthermore, excessive alcohol consumption can irritate the GI tract, potentially worsening the side effects of Orlistat.
Orlistat does not cause physical dependence or a withdrawal syndrome. You can stop taking it at any time without tapering. However, weight regain is common if the patient returns to previous eating habits. It is recommended to discuss a long-term maintenance plan with a dietitian or doctor before stopping the medication.
> Important: Discuss all your medical conditions with your healthcare provider before starting Orlistat, especially if you have a history of eating disorders, gallbladder problems, or kidney stones.
For each major interaction, the management strategy usually involves spacing the doses or increasing the frequency of clinical monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter vitamins and minerals.
Conditions where Orlistat must NEVER be used include:
Conditions requiring careful risk-benefit analysis include:
There are no currently known drugs that share a cross-sensitivity profile with Orlistat, as its chemical structure (a saturated derivative of lipstatin) is unique among weight loss medications. However, patients sensitive to other lipase inhibitors (though few exist in clinical use) should exercise caution.
> Important: Your healthcare provider will evaluate your complete medical history, including your nutritional status and kidney function, before prescribing Orlistat.
Orlistat is contraindicated in pregnancy. According to the FDA, there is no indication for Orlistat use during pregnancy because weight loss offers no potential benefit and may cause fetal harm. If you become pregnant while taking Orlistat, stop the medication immediately and consult your doctor. In animal studies, doses much higher than the human dose did not show teratogenicity (birth defects), but the risk of maternal nutritional deficiency is a major concern.
It is not known whether Orlistat is excreted in human milk. However, because the drug is minimally absorbed into the mother's bloodstream, it is unlikely that significant amounts would reach the breast milk. Nevertheless, because of the potential for interference with the absorption of fat-soluble vitamins in the nursing infant, caution should be exercised. Most healthcare providers recommend avoiding Orlistat while breastfeeding.
The safety and effectiveness of Xenical (120 mg) have been established in adolescents aged 12 to 16 years. Use in this age group should be part of a comprehensive program that includes a healthy diet and exercise. The over-the-counter version (Alli) is not labeled for use in children under 18. There is no data for children under 12, and use in this population is not recommended.
Clinical studies of Orlistat did not include enough subjects aged 65 and older to determine if they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. The risk of vitamin deficiency and subsequent bone density loss is a particular concern in the elderly.
Orlistat is not absorbed in significant amounts, so renal impairment does not affect its pharmacokinetics. However, the risk of oxalate-induced kidney injury is higher in patients with existing renal disease. Patients with a GFR (Glomerular Filtration Rate) of less than 30 mL/min should be monitored closely for signs of worsening kidney function.
No dosage adjustment is required for patients with hepatic impairment. The drug acts locally in the gut and does not rely on the liver for activation or clearance. However, patients should be aware of the rare reports of liver injury associated with Orlistat use.
> Important: Special populations require individualized medical assessment. Always consult with a specialist if you have underlying health conditions.
Orlistat is a potent, specific, and reversible inhibitor of gastric and pancreatic lipases. At the molecular level, it acts in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of these enzymes. The inactivated enzyme is then unable to hydrolyze dietary fat, in the form of triglycerides, into absorbable free fatty acids and monoglycerides. As undigested triglycerides cannot be absorbed, a caloric deficit is created. At the recommended therapeutic dose of 120 mg three times a day, Orlistat inhibits dietary fat absorption by approximately 30%.
The pharmacodynamic effect of Orlistat (measured by the increase in fecal fat) is seen as early as 24 to 48 hours after dosing. Upon discontinuation of therapy, fecal fat content usually returns to pre-treatment levels within 48 to 72 hours. The drug does not appear to affect the absorption of carbohydrates or proteins, nor does it affect the systemic appetite centers of the brain.
| Parameter | Value |
|---|---|
| Bioavailability | < 1% (Minimal systemic absorption) |
| Protein Binding | > 99% (to albumin and lipoproteins) |
| Half-life | 1 - 2 hours (for the absorbed fraction) |
| Tmax | ~8 hours (for the trace plasma levels) |
| Metabolism | Primarily GI wall (Metabolites M1 and M3) |
| Excretion | Fecal 97%, Renal < 2% |
Orlistat is the only member of the Intestinal Lipase Inhibitor [EPC] class currently approved for weight loss. Unlike sympathomimetic amines (like phentermine) or GLP-1 receptor agonists (like semaglutide), Orlistat does not affect the central nervous system or delay gastric emptying. It is unique in its localized, non-systemic approach to weight management.
Common questions about Orlistat
Orlistat is used for weight loss and weight maintenance in individuals who are overweight or obese. It is typically prescribed for adults with a Body Mass Index (BMI) of 30 or higher, or 27 or higher if there are other health risks like diabetes or high blood pressure. The medication works by blocking about 25-30% of the fat you eat from being absorbed by your body. It must be used in combination with a low-calorie, low-fat diet to be effective. It is also available in a lower-dose, over-the-counter version for adults 18 and older.
The most common side effects are gastrointestinal and are directly related to the unabsorbed fat passing through your system. These include oily spotting in undergarments, gas with oily discharge, an urgent need to have a bowel movement, and fatty or oily stools. These effects usually occur within the first few weeks of starting the medication and are more likely to happen if you eat high-fat meals. Many patients find that these side effects decrease as they adjust their diet to include less fat. If these symptoms persist or become severe, you should contact your healthcare provider.
There is no known direct interaction between Orlistat and alcohol that would cause a dangerous chemical reaction. However, alcohol is high in calories and can interfere with your weight loss goals. Additionally, some types of alcohol can irritate the digestive system, which might worsen the gastrointestinal side effects of Orlistat. For the best results in weight management, it is generally recommended to limit alcohol consumption. Always discuss your alcohol intake with your doctor when starting a new medication.
No, Orlistat is contraindicated during pregnancy and should not be used. Weight loss during pregnancy can be harmful to the developing fetus, even if the mother is overweight. If you are planning to become pregnant or find out you are pregnant while taking Orlistat, you should stop the medication immediately. Furthermore, Orlistat can interfere with the absorption of essential vitamins that are crucial for fetal development. Always use effective birth control while taking this medication if you are of childbearing age.
Orlistat begins working within 24 to 48 hours of your first dose, as it starts blocking fat absorption immediately in the gut. However, visible weight loss usually takes a few weeks to become apparent. Clinical studies show that most people see significant weight loss within the first six months of consistent use. It is important to remember that Orlistat only works when taken with meals containing fat. If you do not follow a reduced-calorie diet and exercise plan, the medication will be less effective.
Yes, you can stop taking Orlistat suddenly without experiencing withdrawal symptoms, as it is not a stimulant and does not affect the central nervous system. However, once you stop taking it, your body will begin absorbing 100% of the dietary fat you consume again. This can lead to weight regain if you have not established long-term healthy eating habits. It is best to consult with your healthcare provider before stopping so you can develop a plan to maintain your weight loss. Consistent lifestyle changes are the key to long-term success.
If you miss a dose of Orlistat, you can take it up to one hour after your meal. If more than an hour has passed since your main meal, skip the missed dose and take your next dose at the next meal as scheduled. Do not take a double dose to make up for the one you missed. Since Orlistat only works when there is fat in the digestive tract, taking it too long after a meal or without a meal is not effective. If you frequently miss doses, your weight loss progress may slow down.
Orlistat does not cause weight gain; its pharmacological purpose is to prevent the absorption of calories from fat to promote weight loss. However, if a patient stops taking Orlistat and returns to a high-calorie diet, weight regain is very likely. Some patients may also mistakenly believe they can eat more calories from carbohydrates or proteins because they are taking a 'fat blocker,' which can lead to weight gain. Success with Orlistat requires monitoring your total caloric intake, not just your fat intake. Always work with a doctor or dietitian to ensure your diet is balanced.
Orlistat can interact with several important medications, so you must inform your doctor of everything you are taking. It can significantly reduce the absorption of cyclosporine, levothyroxine, and certain anti-seizure medications. It also affects how warfarin works by changing Vitamin K absorption, which can increase the risk of bleeding. Most interactions can be managed by spacing the doses several hours apart, but some require close monitoring by a professional. Never start or stop other medications without consulting your healthcare provider first.
Yes, Orlistat is available as a generic medication in the 120 mg prescription strength. Generic versions are typically more cost-effective than the brand-name Xenical while providing the same clinical benefits. The 60 mg over-the-counter version is also available in various store brands as a generic equivalent to Alli. All generic versions are required by the FDA to meet the same standards of quality, strength, and purity as the brand-name products. Check with your pharmacist for the most affordable options available to you.